CagriSema beats semaglutide on weight loss, HbA1c in type 2 diabetes trials
CagriSema beats semaglutide on weight loss and HbA1c reduction in type 2 diabetes trials, delivering 4-percentage-point greater weight loss...
Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal
Roche commits $2.3B to co-develop BTK degrader bexobrutideg with Nurix, targeting CLL patients resistant to conventional BTK inhibitors.
Amphista’s AMX-883 BRD9 degrader wins FDA IND clearance for AML
Amphista's AMX-883 BRD9 degrader wins FDA IND clearance for AML, with Phase 1 trials opening in late 2026 targeting...
Cloudbreak Pharma Completes Phase 3 Enrollment for Pterygium Eye Drop CBT-001
Cloudbreak Pharma completes Phase 3 enrollment for CBT-001 eye drop targeting pterygium. Topline data expected Q3 2026 across 660...
Petrelintide achieves 10.7% weight loss with 1.5% GI discontinuation rate in Phase 2
Petrelintide weight loss reaches 10.7% in Phase 2 with only 1.5% GI discontinuation rate, advancing toward Phase 3 trials...
Regeneron Presents Phase 3 Garetosmab Data for Fibrodysplasia Ossificans Progressiva
Regeneron presents Phase 3 garetosmab data for fibrodysplasia ossificans progressiva at ENDO while FDA Priority Review proceeds on the...
Retatrutide Shows 28.3% Weight Loss in Phase 3 Obesity Trial
Retatrutide achieves 28.3% weight loss in Phase 3 obesity trial, significantly exceeding results from competing GLP-1 receptor agonists over...
Climb Bio’s CLYM116 Shows Clean Phase 1 Safety in IgAN Program
CLYM116 Phase 1 safety data shows all adverse events were Grade 1–2 and self-resolving in healthy volunteers dosed up...
Acmopatide Reduces A1C and Weight in Type 1 Diabetes Phase 2 Trial
Acmopatide reduces A1C and weight in Type 1 Diabetes Phase 2 Trial, offering potential insulin-sparing benefits in a 16-week...
Immutep’s IMP761 LAG-3 Agonist Meets Safety Goals in Phase I Trial
IMP761 LAG-3 agonist met safety goals in Phase I trial, showing statistically significant T-cell suppression in healthy volunteers at...